BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia Pivotal Trial Filing for Renevia CE mark by the end of 2017 Positive long-term data in HIV-associated lipoatrophy reinforces Re

Announces Positive Secondary and Additional Positive Long-Term Data from

CE mark by the end of 2017

long-term data in HIV-associated lipoatrophy reinforces Renevia's

potential in multibillion-dollar global facial aesthetics market

ALAMEDA, Calif.--(BUSINESS WIRE)--September 26, 2017--BioTime, Inc.

(NYSE American: BTX), a clinical-stage biotechnology company focused on

developing and commercializing products addressing degenerative

diseases, today announced that treated patients from the Renevia

pivotal trial in Europe retained an average of 70% of the transplanted

volume at 12 months. Additionally, preliminary data for five patients

indicates an average retention of 64% of the transplanted volume at 18

months. These data exceed management expectations for long-term

performance of the Renevia transplant. BioTime remains

on track to file Renevia for CE mark approval by the

The Renevia trial data will be further discussed at the

BioTime presentation at the Ladenburg Thalmann 2017 Healthcare

Conference in New York. The presentation is scheduled for 2:00 pm

ET/11:00 am PT today, September 26, 2017. A live webcast and subsequent

archived replay of the BioTime's presentation may be accessed via the

investor relations section of the BioTime's website at www.investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-EventDetails&EventId=5263572.

"These additional positive data further support our confidence that

Renevia may soon become an important, stable long-term

solution, not only for people with HIV-associated lipoatrophy, but for

people with any facial fat loss, whether caused by pharmaceuticals,

trauma or aging," said BioTime's Co-Chief Executive Officer, Adi

Mohanty. "We are moving quickly to submit an application for a CE mark

to the European regulatory agency, with a possible approval and

commercial launch in 2018."

BioTime previously reported meeting the primary endpoint of this pivotal

trial and now has the remaining required data, secondary endpoints and

safety report to complete the clinical data package necessary to file

for a CE mark in Europe. The secondary endpoints, such as qualitative

improvements, trended positive and support the statistically significant

primary endpoint. Secondary data points were not powered for statistical

significance, but positive trends were seen in both the Mid-Face Volume

Deficit Scale and Body Image Quality of Life Inventory. BioTime remains

on track for filing the CE mark application by the end of this year with

possible approval and launch next year.

In this pivotal trial, BioTime studied patients with HIV-associated

lipoatrophy, which is a severe form of lipoatrophy characterized by the

pathological loss of body fat from under the skin. All Renevia

transplants were well tolerated and there were no device-related serious

adverse events noted in this pivotal trial. The primary endpoint was the

change in hemifacial volume at six months in the treated patients

compared to patients in the delayed treatment arm as measured by 3-D

photographic volumetric assessment. The 3-D volumetric endpoint directly

measures retained volume over time.

The additional data were encouraging as further supporting the

commercial prospects of Renevia , and its potential for

label expansion into other indications, such as cosmetic facial

aesthetics. The facial aesthetics market is estimated to be over 5

billion dollars and growing at or near double digits.

Treated patients received approximately 5cc of Renevia

in each side of the face (hemifacial) and the following table details

the average (mean) volume measured through 18 months.

While only a small number of patients have been observed through 18

months, the results thus far are encouraging.

This positive data, along with the secondary endpoints and full safety

report, will be presented at the upcoming International Federation for

Adipose Therapeutics and Science (IFATS) conference. The IFATS

conference will be held in Miami, FL. from November 30th

through December 3rd of this year.

Renevia is an investigational medical device that is

being developed as an alternative for whole adipose tissue transfer (fat

grafting) procedures. Renevia's hydrogel polymer

network provides the requisite amino acid sequences for adipose stromal

vascular cell attachment and may support proliferation, localization and

adipogenic differentiation. Renevia is part of the

HyStem hydrogel family of proprietary injectable

matrices, which are designed to facilitate the survival and growth of

BioTime is a late stage clinical biotechnology company focused on

developing and commercializing products addressing degenerative

diseases. The Company's current clinical programs are targeting three

primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its

clinical programs are based on two platform technologies: pluripotent

cells, which can become any type of cell in the human body, and

cell/drug delivery. Renevia , a cell delivery product, met its primary

endpoint in an EU pivotal trial for the treatment of facial lipoatrophy

in HIV patients earlier this year. Submission for approval of Renevia

is expected later this year, with an anticipated commercial launch in

2018. OpRegen , a retinal pigment epithelium transplant therapy, is in a

Phase I/IIa multicenter trial for the treatment of dry age-related

macular degeneration, the leading cause of blindness in developing

countries. BioTime also has significant equity holdings in two publicly

traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST)

and OncoCyte Corporation (NYSE American: OCX), and one private company,

AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the

symbol BTX. For more information, please visit www.biotimeinc.com or

connect with the company on Twitter, LinkedIn, Facebook, YouTube,

To receive ongoing BioTime corporate communications, please click on the

following link to join the Company's email alert list: http://news.biotimeinc.com.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking

statements" within the meaning of the Private Securities Litigation

Reform Act of 1995. Statements pertaining to future financial and/or

operating results, future growth in research, technology, clinical

development, and potential opportunities for BioTime, Inc. and its

subsidiaries, along with other statements about the future expectations,